Health
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer – Small Caps
New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned phase 2 clinical trial on pancreatic…
New research describing the fundamental biology behind Amplia Therapeutics (ASX: ATX) planned phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administering…
Continue Reading
-
General15 hours ago‘We are here for you’: PM to bring help to flood zones
-
General13 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News21 hours agoStudents say new facility would be better in rural areas of Queensland
-
Noosa News20 hours agoBrisbane doctor jailed for trafficking ‘breathtaking amount’ of drugs